Fenwick represented Belharra Therapeutics, a privately held drug discovery company with a novel photoaffinity-based, non-covalent chemoproteomics platform, in its multi-year collaboration with Genentech, a member of the Roche group.
The collaboration will focus on discovering and developing small molecule medicines in multiple therapeutic areas including oncology, immuno-oncology, autoimmune and neurodegenerative diseases. Under the terms of the agreement, Belharra will receive an upfront cash payment of $80 million. Over the course of the collaboration, Belharra is eligible to receive development, commercial and net sales milestones that could exceed $2 billion and a tiered royalty on Genentech’s sale of collaboration product. More information about the collaboration can be obtained from Belharra’s announcement.
The Fenwick transaction team was led by life sciences partner Stefano Quintini and included partner Jake Handy and associate Julie Son.